这是一篇来自已证抗体库的有关人类 ER的综述,是根据204篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合ER 抗体。
ER 同义词: ESR; ESRA; ESTRR; Era; NR3A1; estrogen receptor; E2 receptor alpha; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; nuclear receptor subfamily 3 group A member 1; oestrogen receptor alpha

赛默飞世尔
兔 单克隆(Sp1)
  • 其他; 人类; 图 4c
赛默飞世尔 ER抗体(Lab Vision, RM-9101-S)被用于被用于其他在人类样品上 (图 4c). Cancer Cell (2018) ncbi
小鼠 单克隆(1D5)
  • 免疫组化-石蜡切片; 人类; 1:50
赛默飞世尔 ER抗体(Thermo-Scientific, 1D5)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50. J Immunother Cancer (2017) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 1:10; 图 2a
赛默飞世尔 ER抗体(ThermoScientific, RM-9101-S0)被用于被用于免疫印迹在人类样品上浓度为1:10 (图 2a). Nat Commun (2017) ncbi
小鼠 单克隆(EVG F9)
  • 免疫组化-石蜡切片; 兔; 1:150; 表 1
赛默飞世尔 ER抗体(Thermo Scientific, MA3-310)被用于被用于免疫组化-石蜡切片在兔样品上浓度为1:150 (表 1). Biomed Res Int (2017) ncbi
兔 单克隆(Sp1)
  • reverse phase protein lysate microarray; 人类; 图 7a
赛默飞世尔 ER抗体(Lab Vision, RM-9101-S)被用于被用于reverse phase protein lysate microarray在人类样品上 (图 7a). Cancer Cell (2017) ncbi
兔 多克隆
  • 免疫组化-石蜡切片; 大鼠; 1:200; 图 5b
赛默飞世尔 ER抗体(Thermo Fisher Scientific, PA1-309)被用于被用于免疫组化-石蜡切片在大鼠样品上浓度为1:200 (图 5b). J Steroid Biochem Mol Biol (2017) ncbi
小鼠 单克隆(33)
  • 免疫组化-石蜡切片; 大鼠; 图 6a
赛默飞世尔 ER抗体(Thermo Fisher Scientific, MA1-310)被用于被用于免疫组化-石蜡切片在大鼠样品上 (图 6a). Ann Anat (2017) ncbi
兔 单克隆(Sp1)
  • reverse phase protein lysate microarray; 人类; 图 3a
赛默飞世尔 ER抗体(Lab Vision, RM-9101-S)被用于被用于reverse phase protein lysate microarray在人类样品上 (图 3a). Nature (2017) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图 4a
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-SO)被用于被用于免疫印迹在人类样品上 (图 4a). J Cell Biochem (2017) ncbi
小鼠 单克隆(1D5)
  • 免疫细胞化学; 人类; 1:25; 图 6
赛默飞世尔 ER抗体(Thermo Fisher Scientific, 1D5)被用于被用于免疫细胞化学在人类样品上浓度为1:25 (图 6). Oncotarget (2017) ncbi
兔 单克隆(Sp1)
  • 流式细胞仪; 人类; 1:50; 图 ED7c
  • 免疫沉淀; 人类
  • 免疫印迹; 人类; 1:500; 图 2c, 4b, 4e,ED4b
赛默飞世尔 ER抗体(Thermo/Fisher Scientific, SP1)被用于被用于流式细胞仪在人类样品上浓度为1:50 (图 ED7c), 被用于免疫沉淀在人类样品上 和 被用于免疫印迹在人类样品上浓度为1:500 (图 2c, 4b, 4e,ED4b). Nature (2017) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类
赛默飞世尔 ER抗体(Lab Vision, RM-9101-S)被用于被用于免疫印迹在人类样品上. Cell Syst (2017) ncbi
小鼠 单克隆(TE111.5D11)
  • 免疫印迹; 人类; 图 s5c
赛默飞世尔 ER抗体(Thermo Fisher Scientific, TE111.5D11)被用于被用于免疫印迹在人类样品上 (图 s5c). Sci Rep (2016) ncbi
兔 多克隆
  • 免疫组化-冰冻切片; 兔; 1:200; 图 5a
赛默飞世尔 ER抗体(ThermoScientific, PA5-16476)被用于被用于免疫组化-冰冻切片在兔样品上浓度为1:200 (图 5a). J Alzheimers Dis (2017) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-冰冻切片; 兔; 1:200; 图 4a
  • 免疫印迹; 兔; 1:200; 图 4d
赛默飞世尔 ER抗体(ThermoScientific, MA1-27107)被用于被用于免疫组化-冰冻切片在兔样品上浓度为1:200 (图 4a) 和 被用于免疫印迹在兔样品上浓度为1:200 (图 4d). J Alzheimers Dis (2017) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:500; 表 1
赛默飞世尔 ER抗体(Thermo Scientific, MA1-39540)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:500 (表 1). ESMO Open (2016) ncbi
小鼠 单克隆(1D5)
  • 免疫印迹; 人类; 1:500; 表 1
赛默飞世尔 ER抗体(Thermo Scientific, MS-354)被用于被用于免疫印迹在人类样品上浓度为1:500 (表 1). Endocrinology (2016) ncbi
兔 多克隆
  • 免疫组化; 小鼠; 图 2a
赛默飞世尔 ER抗体(Thermo Fisher, PA1-308)被用于被用于免疫组化在小鼠样品上 (图 2a). Endocrinology (2016) ncbi
小鼠 单克隆(TE111.5D11)
  • 免疫印迹; 小鼠; 图 1d
  • 免疫组化-冰冻切片; 人类; 图 1a
赛默飞世尔 ER抗体(ThermoFisher Scientific, TE111.5D11)被用于被用于免疫印迹在小鼠样品上 (图 1d) 和 被用于免疫组化-冰冻切片在人类样品上 (图 1a). Cancer Discov (2017) ncbi
小鼠 单克隆(TE111.5D11)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔 ER抗体(Thermo Scientific, TE111.5D11)被用于被用于流式细胞仪在人类样品上 (图 1a). J Gen Virol (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 图 st1
赛默飞世尔 ER抗体(Thermo scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上 (图 st1). Clin Cancer Res (2017) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 表 2
赛默飞世尔 ER抗体(Thermo Fisher Scientific, ER-RM-9101-S1)被用于被用于免疫组化-石蜡切片在人类样品上 (表 2). Mol Diagn Ther (2016) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图 2
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S)被用于被用于免疫印迹在人类样品上 (图 2). J Cancer (2016) ncbi
小鼠 单克隆(1D5)
  • 免疫组化; 人类; 1:300; 图 2
赛默飞世尔 ER抗体(Thermo, 1D5)被用于被用于免疫组化在人类样品上浓度为1:300 (图 2). Diagn Pathol (2016) ncbi
小鼠 单克隆(33)
  • 免疫细胞化学; 小鼠; 1:50; 图 5
赛默飞世尔 ER抗体(Thermo Scientific, MA1-310)被用于被用于免疫细胞化学在小鼠样品上浓度为1:50 (图 5). Mol Cell Endocrinol (2016) ncbi
小鼠 单克隆(33)
  • 流式细胞仪; 人类; 1:20
赛默飞世尔 ER抗体(Thermo, MA1310)被用于被用于流式细胞仪在人类样品上浓度为1:20. Nat Commun (2016) ncbi
小鼠 单克隆(TE111.5D11)
  • 染色质免疫沉淀 ; 小鼠; 图 1a
赛默飞世尔 ER抗体(Thermo Scientific, TE111.5D11)被用于被用于染色质免疫沉淀 在小鼠样品上 (图 1a). Cell Rep (2016) ncbi
小鼠 单克隆(TE111.5D11)
  • ChIP-Seq; 人类; 图 5a
赛默飞世尔 ER抗体(Thermo Scientific, MA5-13065)被用于被用于ChIP-Seq在人类样品上 (图 5a). Mol Oncol (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 s2
赛默飞世尔 ER抗体(Thermo Sc. Labvision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 s2). J Exp Clin Cancer Res (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:200; 表 1
赛默飞世尔 ER抗体(ThermoFisher Scientific, MA1-39540)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200 (表 1). Oncol Lett (2016) ncbi
小鼠 单克隆(33)
  • 免疫印迹; 猪; 图 3
赛默飞世尔 ER抗体(Pierce, MA1-310)被用于被用于免疫印迹在猪样品上 (图 3). J Biol Chem (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 s1
赛默飞世尔 ER抗体(Neomarkers, RM-9101-S1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 s1). BMC Cancer (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:100
赛默飞世尔 ER抗体(Thermoscientific, SP1)被用于被用于免疫组化在人类样品上浓度为1:100. Breast Cancer Res Treat (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 表 3
赛默飞世尔 ER抗体(ThermoScientific, RM-9101)被用于被用于免疫组化在人类样品上 (表 3). PLoS ONE (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Ann Surg Oncol (2016) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 猫; 1:125; 表 4
赛默飞世尔 ER抗体(Thermo Scientific, 6F11)被用于被用于免疫组化-石蜡切片在猫样品上浓度为1:125 (表 4). Oncotarget (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 1
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (表 1). Pathol Oncol Res (2016) ncbi
兔 单克隆(Sp1)
  • 免疫细胞化学; 人类; 1:10; 图 s13b
赛默飞世尔 ER抗体(Labvision, RM-9101-S)被用于被用于免疫细胞化学在人类样品上浓度为1:10 (图 s13b). Nat Commun (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • 免疫组化-石蜡切片; 鸡; 4 ug/ml; 图 3
赛默飞世尔 ER抗体(NeoMarkers, TE111.5D11)被用于被用于免疫组化-石蜡切片在鸡样品上浓度为4 ug/ml (图 3). Acta Histochem (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Thermo Fisher, RM-9101-S)被用于被用于免疫组化-石蜡切片在人类样品上. Ann Oncol (2016) ncbi
小鼠 单克隆(6F11)
  • 免疫组化; 猫; 1:100; 图 1a
赛默飞世尔 ER抗体(Thermo Scientific, 6 F11)被用于被用于免疫组化在猫样品上浓度为1:100 (图 1a). Tumour Biol (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 2). PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上. Oncotarget (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类
赛默飞世尔 ER抗体(Thermo scientific, SP1)被用于被用于免疫组化在人类样品上. Ecancermedicalscience (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • 染色质免疫沉淀 ; 小鼠; 图 1h
  • 免疫印迹; 小鼠; 图 1d
赛默飞世尔 ER抗体(Thermo Scientific, TE111.5D11)被用于被用于染色质免疫沉淀 在小鼠样品上 (图 1h) 和 被用于免疫印迹在小鼠样品上 (图 1d). J Clin Invest (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • 染色质免疫沉淀 ; 小鼠; 图 1h
  • 免疫印迹; 小鼠; 图 1d
赛默飞世尔 ER抗体(Thermo Scientific, TE111.5D11)被用于被用于染色质免疫沉淀 在小鼠样品上 (图 1h) 和 被用于免疫印迹在小鼠样品上 (图 1d). Oncogene (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S1)被用于被用于免疫组化在人类样品上浓度为1:100. Pathol Res Pract (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:60
赛默飞世尔 ER抗体(Thermo Fisher Scientific, RM9101S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:60. Clin Cancer Res (2015) ncbi
小鼠 单克隆(6F11)
  • 免疫组化; 猪; 图 s5
赛默飞世尔 ER抗体(ThermoFisher Scientific, 6F11)被用于被用于免疫组化在猪样品上 (图 s5). BMC Cancer (2015) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图 2
赛默飞世尔 ER抗体(Thermo Scientific, RM9101S0)被用于被用于免疫印迹在人类样品上 (图 2). Cell Death Dis (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:25; 图 1c
赛默飞世尔 ER抗体(Thermo Scientific, clone SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:25 (图 1c). J Biomed Sci (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:500
赛默飞世尔 ER抗体(NeoMarkers, RM9101)被用于被用于免疫组化在人类样品上浓度为1:500. Mol Clin Oncol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:50; 表 2
赛默飞世尔 ER抗体(Thermo Lab Vision, RM-9101-S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (表 2). Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:50
赛默飞世尔 ER抗体(Thermo Scientific Lab Vision, RM-9101-S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:500
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化在人类样品上浓度为1:500. Breast (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Thermo Scientific Lab Vision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上. Niger J Clin Pract (2015) ncbi
兔 单克隆(Sp1)
  • 免疫细胞化学; 人类; 1:50
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S1)被用于被用于免疫细胞化学在人类样品上浓度为1:50. J Transl Med (2015) ncbi
小鼠 单克隆(33)
  • 免疫印迹; 人类
赛默飞世尔 ER抗体(Thermo Scientific, MA1-310)被用于被用于免疫印迹在人类样品上. BMC Cancer (2015) ncbi
小鼠 单克隆(EVG F9)
  • 免疫组化; 兔
赛默飞世尔 ER抗体(Thermo Scientific, MA3-310)被用于被用于免疫组化在兔样品上. Cell Biochem Funct (2015) ncbi
小鼠 单克隆(6F11)
  • 免疫细胞化学; 大鼠
赛默飞世尔 ER抗体(Thermo Scientific, 6F11)被用于被用于免疫细胞化学在大鼠样品上. Exp Oncol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:80
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化在人类样品上浓度为1:80. Gynecol Oncol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 ER抗体(LabVision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Cancer Res Treat (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Lab Vision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上. Pathol Oncol Res (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 4
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (表 4). PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 表 3
赛默飞世尔 ER抗体(NeoMarkers, RM-9101-S1)被用于被用于免疫组化-石蜡切片在人类样品上 (表 3). PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:50
赛默飞世尔 ER抗体(Neomarker, RM-9101-R7)被用于被用于免疫组化在人类样品上浓度为1:50. Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:80
赛默飞世尔 ER抗体(Thermo Fisher Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:80. Int J Gynecol Pathol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:400
赛默飞世尔 ER抗体(Thermo, SP1)被用于被用于免疫组化在人类样品上浓度为1:400. Balkan Med J (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101)被用于被用于免疫组化在人类样品上浓度为1:100. Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图 3
赛默飞世尔 ER抗体(Neomarkers, RM-9101)被用于被用于免疫印迹在人类样品上 (图 3). Int J Oncol (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • 染色质免疫沉淀 ; 人类
赛默飞世尔 ER抗体(Thermo, MA5?C13062)被用于被用于染色质免疫沉淀 在人类样品上. Cell Death Differ (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:200
赛默飞世尔 ER抗体(Zymed, SP1)被用于被用于免疫组化在人类样品上浓度为1:200. Breast Cancer Res Treat (2015) ncbi
小鼠 单克隆(6F11)
  • 免疫组化; 人类
  • 免疫组化; 大鼠
赛默飞世尔 ER抗体(Thermo Scientific, 6F11)被用于被用于免疫组化在人类样品上 和 被用于免疫组化在大鼠样品上. Exp Oncol (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:50
赛默飞世尔 ER抗体(Thermo Fisher Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Oncotarget (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:500
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化在人类样品上浓度为1:500. BMC Womens Health (2014) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:3000
赛默飞世尔 ER抗体(生活技术, 49-1002)被用于被用于免疫组化在人类样品上浓度为1:3000. Dev Neurobiol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, SP-1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Am J Clin Pathol (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2
赛默飞世尔 ER抗体(NeoMarkers, RM-9101-SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 2). PLoS ONE (2014) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类
赛默飞世尔 ER抗体(Thermo, SP1)被用于被用于免疫印迹在人类样品上. Oncotarget (2014) ncbi
小鼠 单克隆(TE111.5D11)
  • 免疫沉淀; 人类; 1:200
赛默飞世尔 ER抗体(Thermo, MA5-13065)被用于被用于免疫沉淀在人类样品上浓度为1:200. Nat Med (2014) ncbi
小鼠 单克隆(33)
  • 免疫细胞化学; 人类; 1:200
  • 免疫印迹; 小鼠; 1:200
赛默飞世尔 ER抗体(Thermo, MA1-310)被用于被用于免疫细胞化学在人类样品上浓度为1:200 和 被用于免疫印迹在小鼠样品上浓度为1:200. Nat Med (2014) ncbi
小鼠 单克隆(TE111.5D11)
  • 染色质免疫沉淀 ; 猪
  • 免疫印迹; 猪; 1:500
赛默飞世尔 ER抗体(Thermo, MA5-13065)被用于被用于染色质免疫沉淀 在猪样品上 和 被用于免疫印迹在猪样品上浓度为1:500. J Steroid Biochem Mol Biol (2014) ncbi
小鼠 单克隆(H4624)
  • 流式细胞仪; 羊; 1:10
  • 免疫组化; 羊; 1:50
赛默飞世尔 ER抗体(Invitrogen, 41700)被用于被用于流式细胞仪在羊样品上浓度为1:10 和 被用于免疫组化在羊样品上浓度为1:50. Microsc Res Tech (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:80
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化在人类样品上浓度为1:80. Virchows Arch (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:500
赛默飞世尔 ER抗体(LabVision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:500. Br J Cancer (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Thermo, SP1)被用于被用于免疫组化-石蜡切片在人类样品上. Lab Invest (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 ER抗体(Lab Vision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200. APMIS (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 ER抗体(Labvision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Mod Pathol (2014) ncbi
小鼠 单克隆(AER314)
  • 免疫印迹; 人类; 图 s8
赛默飞世尔 ER抗体(Thermo Fisher, AER314)被用于被用于免疫印迹在人类样品上 (图 s8). Nat Commun (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类
赛默飞世尔 ER抗体(Thermo Scientific, SP-1)被用于被用于免疫组化在人类样品上. Head Neck (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:60
赛默飞世尔 ER抗体(Thermo Fisher, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:60. Int J Cancer (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:200; 图 2
赛默飞世尔 ER抗体(Zymed, clone SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200 (图 2). Int J Clin Exp Pathol (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于被用于免疫组化-石蜡切片在人类样品上. J BUON (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:500; 表 1
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:500 (表 1). Clinics (Sao Paulo) (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类
赛默飞世尔 ER抗体(Zymed, SP1)被用于被用于免疫组化在人类样品上. Cancer Biol Med (2012) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:50; 图 1
赛默飞世尔 ER抗体(Neomarkers, RM-9101-S1)被用于被用于免疫组化在人类样品上浓度为1:50 (图 1). Br J Cancer (2013) ncbi
小鼠 单克隆(1D5)
  • 免疫组化; 人类; 表 1
赛默飞世尔 ER抗体(Zymed, 1D5)被用于被用于免疫组化在人类样品上 (表 1). Int J Surg Pathol (2014) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 ER抗体(Zymed Laboratories, 491002)被用于被用于免疫组化-石蜡切片在人类样品上. PLoS ONE (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 1). Oncol Rep (2013) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔 ER抗体(Neomarkers, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 1). Oncol Rep (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 图 2d
  • 免疫组化; 人类; 1:1000
  • 免疫印迹; 人类; 1:500; 图 1b
赛默飞世尔 ER抗体(Thermo, SP1)被用于被用于免疫组化-石蜡切片在人类样品上 (图 2d), 被用于免疫组化在人类样品上浓度为1:1000 和 被用于免疫印迹在人类样品上浓度为1:500 (图 1b). Appl Immunohistochem Mol Morphol (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:1000
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于被用于免疫组化在人类样品上浓度为1:1000. Clin Med Insights Case Rep (2012) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
赛默飞世尔 ER抗体(NeoMarkers, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 1). Diagn Pathol (2011) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:50
赛默飞世尔 ER抗体(Neomarker, RM9101-S)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Breast Cancer Res (2011) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图 1
赛默飞世尔 ER抗体(Lab Vision, SP1)被用于被用于免疫印迹在人类样品上 (图 1). Endocr Relat Cancer (2010) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 表 1
赛默飞世尔 ER抗体(Labvision, SP1)被用于被用于免疫组化-石蜡切片在人类样品上 (表 1). Pathology (2010) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:400; 表 3
  • 免疫组化; 人类; 1:400
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:400 (表 3) 和 被用于免疫组化在人类样品上浓度为1:400. Histopathology (2008) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-冰冻切片; 人类; 1:100
  • 免疫组化; 人类; 1:100
赛默飞世尔 ER抗体(Lab Vision, 6F11)被用于被用于免疫组化-冰冻切片在人类样品上浓度为1:100 和 被用于免疫组化在人类样品上浓度为1:100. Am J Clin Pathol (2008) ncbi
兔 单克隆(Sp1)
  • 免疫细胞化学; 人类; 图 5
  • 免疫组化; 人类
  • 免疫印迹; 人类
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于被用于免疫细胞化学在人类样品上 (图 5), 被用于免疫组化在人类样品上 和 被用于免疫印迹在人类样品上. Breast Cancer Res (2007) ncbi
小鼠 单克隆(1D5)
  • 免疫组化-石蜡切片; 人类; 1:200
赛默飞世尔 ER抗体(Zymed, ID5)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Cancer Cell Int (2006) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 1:80; 图 6
赛默飞世尔 ER抗体(Zymed, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:80 (图 6). Am J Surg Pathol (2004) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 大鼠; 表 1
赛默飞世尔 ER抗体(Zymed, 6F11)被用于被用于免疫组化-石蜡切片在大鼠样品上 (表 1). Biol Reprod (2004) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 表 2
赛默飞世尔 ER抗体(Zymed, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上 (表 2). Int J Gynecol Cancer (2003) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 表 1
赛默飞世尔 ER抗体(Zymed, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上 (表 1). Histopathology (2002) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 图 1
赛默飞世尔 ER抗体(Zymed, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Int J Gynecol Pathol (2001) ncbi
小鼠 单克隆(AER314)
  • 免疫印迹基因敲除验证; 人类; 图 4
赛默飞世尔 ER抗体(Neomarkers, AER314)被用于被用于免疫印迹基因敲除验证在人类样品上 (图 4). Clin Cancer Res (1996) ncbi
圣克鲁斯生物技术
小鼠 单克隆(D-12)
  • 免疫细胞化学; 人类; 1:50
  • 免疫印迹; 人类; 图 2a
圣克鲁斯生物技术 ER抗体(SantaCruz, sc8005)被用于被用于免疫细胞化学在人类样品上浓度为1:50 和 被用于免疫印迹在人类样品上 (图 2a). Breast Cancer Res Treat (2018) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 图 1c
圣克鲁斯生物技术 ER抗体(SantaCruz, sc-8005)被用于被用于免疫印迹在人类样品上 (图 1c). Oncotarget (2017) ncbi
小鼠 单克隆(D-12)
  • EMSA; 人类; 图 8a
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005X)被用于被用于EMSA在人类样品上 (图 8a). Nat Commun (2017) ncbi
小鼠 单克隆(10H12B10)
  • 免疫印迹; 人类; 1:1000; 图 7d
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-130072)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 7d). Front Pharmacol (2017) ncbi
小鼠 单克隆(D-12)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 4a
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 4a). Reprod Biol Endocrinol (2017) ncbi
小鼠 单克隆(C-311)
  • 免疫细胞化学; 猪; 1:50; 图 2
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, C-311)被用于被用于免疫细胞化学在猪样品上浓度为1:50 (图 2). PLoS ONE (2017) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 1:300; 图 1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-56836)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:300 (图 1). Arch Med Sci (2017) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图 3b
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上 (图 3b). Oncotarget (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图 2
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上 (图 2). PLoS ONE (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫组化-石蜡切片; 人类; 1:500; 图 1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:500 (图 1). Oncol Lett (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图 1
圣克鲁斯生物技术 ER抗体(santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上 (图 1). Breast Cancer Res (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:750; 图 1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上浓度为1:750 (图 1). Breast Cancer Res Treat (2016) ncbi
小鼠 单克隆(F-10)
  • 染色质免疫沉淀 ; 人类; 图 3
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8002X)被用于被用于染色质免疫沉淀 在人类样品上 (图 3). PLoS ONE (2016) ncbi
小鼠 单克隆(C-311)
  • 免疫印迹; 小鼠; 1:1000; 图 7
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc787)被用于被用于免疫印迹在小鼠样品上浓度为1:1000 (图 7). Sci Rep (2016) ncbi
大鼠 单克隆(H226)
  • 免疫组化-石蜡切片; baboons; 图 4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-53493)被用于被用于免疫组化-石蜡切片在baboons样品上 (图 4). Oncotarget (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹基因敲除验证; 人类; 图 1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹基因敲除验证在人类样品上 (图 1). PLoS ONE (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 1:1000; 图 6
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 6). Breast Cancer Res (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫细胞化学; 人类; 图 1
  • 免疫印迹; 人类; 图 5
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc8005)被用于被用于免疫细胞化学在人类样品上 (图 1) 和 被用于免疫印迹在人类样品上 (图 5). Oncogene (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:200; 图 2
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上浓度为1:200 (图 2). J Immunol Res (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫细胞化学; 人类; 图 3d
  • 免疫印迹; 人类; 图 3c
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫细胞化学在人类样品上 (图 3d) 和 被用于免疫印迹在人类样品上 (图 3c). Oncogene (2016) ncbi
小鼠 单克隆(D-12)
  • 染色质免疫沉淀 ; 人类; 图 4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005X)被用于被用于染色质免疫沉淀 在人类样品上 (图 4). Oncogene (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 图 1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫印迹在人类样品上 (图 1). Front Endocrinol (Lausanne) (2015) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 小鼠; 1:300
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫印迹在小鼠样品上浓度为1:300. Reprod Sci (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 图 2b, s1c
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, ESR1)被用于被用于免疫印迹在人类样品上 (图 2b, s1c). Endocr Relat Cancer (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图 3
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上 (图 3). Oncotarget (2015) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8005)被用于被用于免疫印迹在人类样品上. J Biol Chem (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图 1a
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上 (图 1a). Oncotarget (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:1000; 图 4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002 F-10)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 4). PLoS ONE (2015) ncbi
小鼠 单克隆(2Q418)
  • 染色质免疫沉淀 ; 人类; 图 5
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, 2Q418)被用于被用于染色质免疫沉淀 在人类样品上 (图 5). Biochim Biophys Acta (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图 s2b
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上 (图 s2b). Environ Health Perspect (2015) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫印迹在人类样品上. Cell Oncol (Dordr) (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 小鼠; 图 6
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8002)被用于被用于免疫印迹在小鼠样品上 (图 6). elife (2014) ncbi
小鼠 单克隆(2Q418)
  • 免疫印迹; 人类; 1:500; 图 3
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-71064)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 3). Mol Autism (2014) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:200
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上浓度为1:200. Cell Oncol (Dordr) (2014) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002X)被用于被用于免疫印迹在小鼠样品上. J Immunol (2014) ncbi
小鼠 单克隆(D-12)
  • 免疫组化-石蜡切片; 人类; 1:75
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:75. Int J Cancer (2014) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上. Nucleic Acids Res (2014) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 图 4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于被用于免疫印迹在人类样品上 (图 4). Mol Endocrinol (2007) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:400; 图 6
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于被用于免疫印迹在人类样品上浓度为1:400 (图 6). Oncogene (2005) ncbi
艾博抗(上海)贸易有限公司
兔 单克隆(E91)
  • 其他; 人类; 图 4c
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab32396)被用于被用于其他在人类样品上 (图 4c). Cancer Cell (2018) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:5; 图 2a
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab27595)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:5 (图 2a). Cell (2018) ncbi
兔 单克隆(E91)
  • 免疫印迹; 人类; 图 1d
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab32396)被用于被用于免疫印迹在人类样品上 (图 1d). Oncotarget (2017) ncbi
兔 单克隆(E115)
  • 免疫印迹; 大鼠; 1:1000; 图 5b
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab32063)被用于被用于免疫印迹在大鼠样品上浓度为1:1000 (图 5b). Toxins (Basel) (2017) ncbi
兔 单克隆(Sp1)
  • 免疫组化-冰冻切片; 小鼠; 1:100; 图 s2a
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab27595)被用于被用于免疫组化-冰冻切片在小鼠样品上浓度为1:100 (图 s2a). Nat Commun (2016) ncbi
兔 单克隆(E115)
  • 免疫组化-石蜡切片; 小鼠; 1:150; 图 5a
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab32063)被用于被用于免疫组化-石蜡切片在小鼠样品上浓度为1:150 (图 5a). Biol Reprod (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-冰冻切片; 小鼠; 1:100; 图 S3
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab27595)被用于被用于免疫组化-冰冻切片在小鼠样品上浓度为1:100 (图 S3). Nat Commun (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 5s
艾博抗(上海)贸易有限公司 ER抗体(Abcam, 16660)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图 5s). Sci Rep (2016) ncbi
兔 多克隆
  • 免疫组化; 小鼠; 1:100; 图 1
  • 免疫印迹; 小鼠; 1:500; 图 1
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab75635)被用于被用于免疫组化在小鼠样品上浓度为1:100 (图 1) 和 被用于免疫印迹在小鼠样品上浓度为1:500 (图 1). Sci Rep (2016) ncbi
兔 单克隆(E115)
  • 染色质免疫沉淀 ; 人类; 图 3e
  • 免疫印迹; 人类; 图 2a
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab32063)被用于被用于染色质免疫沉淀 在人类样品上 (图 3e) 和 被用于免疫印迹在人类样品上 (图 2a). PLoS ONE (2016) ncbi
兔 单克隆(Sp1)
  • 免疫细胞化学; 小鼠
艾博抗(上海)贸易有限公司 ER抗体(Abcam, AB27595)被用于被用于免疫细胞化学在小鼠样品上. PLoS ONE (2015) ncbi
兔 多克隆
  • 免疫细胞化学; 人类; 图 2
  • 免疫印迹; 人类; 图 2
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab75635)被用于被用于免疫细胞化学在人类样品上 (图 2) 和 被用于免疫印迹在人类样品上 (图 2). Reproduction (2015) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图 4
艾博抗(上海)贸易有限公司 ER抗体(abcam, ab16660)被用于被用于免疫印迹在人类样品上 (图 4). Cancer Biol Ther (2015) ncbi
兔 单克隆(Sp1)
  • 免疫细胞化学; 人类; 1:100
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab16660)被用于被用于免疫细胞化学在人类样品上浓度为1:100. Front Cell Dev Biol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-冰冻切片; scFv; 1:1; 图 1
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab27595)被用于被用于免疫组化-冰冻切片在scFv样品上浓度为1:1 (图 1). Nat Commun (2015) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类
艾博抗(上海)贸易有限公司 ER抗体(Abcam, SP-1)被用于被用于免疫印迹在人类样品上. Breast Cancer Res (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-石蜡切片; 人类
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab16660)被用于被用于免疫组化-石蜡切片在人类样品上. PLoS ONE (2014) ncbi
兔 单克隆(E115)
  • 免疫印迹; 小鼠; 1:1000
艾博抗(上海)贸易有限公司 ER抗体(Abcam, Ab32063)被用于被用于免疫印迹在小鼠样品上浓度为1:1000. Neuroscience (2014) ncbi
Active Motif
小鼠 单克隆(F3)
  • 染色质免疫沉淀 ; 人类; 图 6
Active Motif ER抗体(Active Motif, 61035)被用于被用于染色质免疫沉淀 在人类样品上 (图 6). Nat Commun (2016) ncbi
小鼠 单克隆(F3)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类; 1:500
Active Motif ER抗体(Active Motif, 61035)被用于被用于免疫沉淀在人类样品上 和 被用于免疫印迹在人类样品上浓度为1:500. Lupus (2013) ncbi
武汉三鹰
兔 多克隆
  • 免疫组化-石蜡切片; 牛; 1:50; 图 6
武汉三鹰 ER抗体(Proteintech, 21244-1-AP)被用于被用于免疫组化-石蜡切片在牛样品上浓度为1:50 (图 6). Sci Rep (2016) ncbi
Bethyl
兔 多克隆
  • 免疫印迹; 人类; 图 '2e', '4b'
Bethyl ER抗体(Bethyl Labs, A300-498A)被用于被用于免疫印迹在人类样品上 (图 '2e', '4b'). Mol Oncol (2016) ncbi
安迪生物R&D
羊 多克隆
  • proximity ligation assay; 人类
安迪生物R&D ER抗体(R&D Systems, AF5715)被用于被用于proximity ligation assay在人类样品上. BMC Cancer (2014) ncbi
赛信通(上海)生物试剂有限公司
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 图 4a
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 8644)被用于被用于免疫印迹在人类样品上 (图 4a). J Cell Biochem (2017) ncbi
兔 单克隆(D8H8)
  • 免疫沉淀; 人类; 图 ED8g
  • 免疫印迹; 人类; 1:500; 图 2c, 4b, 4e,ED4b
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 8644)被用于被用于免疫沉淀在人类样品上 (图 ED8g) 和 被用于免疫印迹在人类样品上浓度为1:500 (图 2c, 4b, 4e,ED4b). Nature (2017) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 1:1000; 图 4C
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 8644)被用于被用于免疫印迹在人类样品上浓度为1:1000 (图 4C). Oncotarget (2017) ncbi
兔 单克隆(D1A3)
  • 免疫印迹; 人类; 1:500; 图 4e
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signalling, 5587)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 4e). Oncogene (2017) ncbi
小鼠 单克隆(16J4)
  • 免疫印迹; 人类; 1:500; 图 4e
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signalling, 2511)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 4e). Oncogene (2017) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 图 2g
赛信通(上海)生物试剂有限公司 ER抗体(Cell signaling, 8644)被用于被用于免疫印迹在人类样品上 (图 2g). Oncogene (2017) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 1:1000; 表 s6
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 8644)被用于被用于免疫印迹在人类样品上浓度为1:1000 (表 s6). PLoS Genet (2016) ncbi
小鼠 单克隆(16J4)
  • 免疫印迹; 人类; 图 S1a
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signalling, 2511)被用于被用于免疫印迹在人类样品上 (图 S1a). Oncotarget (2016) ncbi
兔 单克隆(D1A3)
  • 免疫印迹; 人类; 图 4b
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 5587P)被用于被用于免疫印迹在人类样品上 (图 4b). Oncotarget (2016) ncbi
小鼠 单克隆(16J4)
  • 流式细胞仪; 牛; 1:50; 图 6
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 2511S)被用于被用于流式细胞仪在牛样品上浓度为1:50 (图 6). Mediators Inflamm (2016) ncbi
小鼠 单克隆(16J4)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 s1
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2511)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 s1). BMC Cancer (2016) ncbi
兔 多克隆
  • 免疫印迹; 人类; 图 5
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2517S)被用于被用于免疫印迹在人类样品上 (图 5). Oncogene (2016) ncbi
小鼠 单克隆(16J4)
  • 免疫印迹; 人类; 图 4
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2511S)被用于被用于免疫印迹在人类样品上 (图 4). Oncogene (2016) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 大鼠; 1:500; 图 s2
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 8644)被用于被用于免疫印迹在大鼠样品上浓度为1:500 (图 s2). Life Sci (2015) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 图 1
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signal, D8H8)被用于被用于免疫印迹在人类样品上 (图 1). PLoS ONE (2015) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 8644)被用于被用于免疫印迹在人类样品上. Cell Death Dis (2014) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, D8H8)被用于被用于免疫印迹在人类样品上. Cell Biochem Biophys (2015) ncbi
小鼠 单克隆(16J4)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2511)被用于被用于免疫印迹在人类样品上. Oncogene (2014) ncbi
默克密理博中国
兔 单克隆(60C)
  • 免疫印迹; 人类; 图 2a; 2g
默克密理博中国 ER抗体(Millipore, 04-820)被用于被用于免疫印迹在人类样品上 (图 2a; 2g). Oncotarget (2016) ncbi
小鼠 单克隆(AER314)
  • 免疫沉淀; 人类; 图 6c
  • 免疫细胞化学; 人类; 图 4
  • 免疫印迹; 人类; 图 2e
默克密理博中国 ER抗体(Millipore, 4.47)被用于被用于免疫沉淀在人类样品上 (图 6c), 被用于免疫细胞化学在人类样品上 (图 4) 和 被用于免疫印迹在人类样品上 (图 2e). Stem Cells (2016) ncbi
小鼠 单克隆
  • 免疫组化; 小鼠; 1:100; 图 2
默克密理博中国 ER抗体(Millipore, 17-603)被用于被用于免疫组化在小鼠样品上浓度为1:100 (图 2). Sci Rep (2016) ncbi
兔 多克隆
  • 免疫细胞化学; 人类; 1:100
  • 免疫印迹; 人类; 1:1000
默克密理博中国 ER抗体(Upstate Merck Millipore, #07-481)被用于被用于免疫细胞化学在人类样品上浓度为1:100 和 被用于免疫印迹在人类样品上浓度为1:1000. Breast Cancer Res (2014) ncbi
西格玛奥德里奇
兔 多克隆
  • 免疫组化-石蜡切片; 牛; 图 2b
西格玛奥德里奇 ER抗体(Sigma-Aldrich, SAB2100712)被用于被用于免疫组化-石蜡切片在牛样品上 (图 2b). Reproduction (2016) ncbi
徕卡显微系统(上海)贸易有限公司
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 6e
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 6e). J Pathol (2017) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 1:50; 图 3
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, Leica Biosystem, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图 3). Taiwan J Obstet Gynecol (2016) ncbi
小鼠 单克隆(6F11)
  • 免疫印迹; 人类; 图 s6
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Biosystems, 6 F11)被用于被用于免疫印迹在人类样品上 (图 s6). Breast Cancer Res (2016) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-石蜡切片; 人类; 1:50; 表 s5
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (表 s5). Oncotarget (2016) ncbi
小鼠 单克隆
  • 免疫印迹; 人类; 图 3c
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Biosystems, NCL-L-ER-6F11)被用于被用于免疫印迹在人类样品上 (图 3c). Clin Cancer Res (2016) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:50
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Biosystems, 6F11)被用于被用于免疫组化在人类样品上浓度为1:50. Hum Pathol (2015) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:400
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, NCL-L-ER-6F11)被用于被用于免疫组化在人类样品上浓度为1:400. Pathol Oncol Res (2015) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:200
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Microsystems, 6 F11)被用于被用于免疫组化在人类样品上浓度为1:200. J Ovarian Res (2015) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 大鼠
徕卡显微系统(上海)贸易有限公司 ER抗体(Novacastra, NCL-L-ER-6F11)被用于被用于免疫组化-石蜡切片在大鼠样品上. Prostate (2015) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 人类
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, NCL-L-ER-6F11)被用于被用于免疫组化-石蜡切片在人类样品上. BMC Cancer (2014) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 人类
徕卡显微系统(上海)贸易有限公司 ER抗体(Germany Leica, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上. Cell Biochem Biophys (2015) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 人类; 1:35
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:35. Hum Pathol (2014) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 人类; 1:200
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Microsystems, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Virchows Arch (2014) ncbi
小鼠 单克隆
  • 免疫组化; 人类
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于被用于免疫组化在人类样品上. Breast Cancer Res Treat (2014) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:200
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于被用于免疫组化在人类样品上浓度为1:200. Horm Cancer (2014) ncbi
小鼠 单克隆
  • 免疫组化-石蜡切片; 人类; 1:300
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:300. Korean J Pathol (2013) ncbi
文章列表
  1. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed 出版商
  2. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373-386.e10 pubmed 出版商
  3. Bostner J, Alayev A, Berman A, Fornander T, Nordenskjold B, Holz M, et al. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2018;168:17-27 pubmed 出版商
  4. Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman J. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017;8:72281-72301 pubmed 出版商
  5. Carvajal Hausdorf D, Mani N, Velcheti V, Schalper K, Rimm D. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017;5:81 pubmed 出版商
  6. Pasutto F, Zenkel M, Hoja U, Berner D, Uebe S, Ferrazzi F, et al. Pseudoexfoliation syndrome-associated genetic variants affect transcription factor binding and alternative splicing of LOXL1. Nat Commun. 2017;8:15466 pubmed 出版商
  7. Ferraiuolo R, Tubman J, Sinha I, Hamm C, Porter L. The cyclin-like protein, SPY1, regulates the ER? and ERK1/2 pathways promoting tamoxifen resistance. Oncotarget. 2017;8:23337-23352 pubmed 出版商
  8. Sinkala E, Sollier Christen E, Renier C, Rosàs Canyelles E, Che J, Heirich K, et al. Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun. 2017;8:14622 pubmed 出版商
  9. Gilligan L, Gondal A, Tang V, Hussain M, Arvaniti A, Hewitt A, et al. Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy. Front Pharmacol. 2017;8:103 pubmed 出版商
  10. Hernández Aragón L, García Villamar V, Carrasco Ruiz M, Nicolás Toledo L, Ortega A, Cuevas Romero E, et al. Role of Estrogens in the Size of Neuronal Somata of Paravaginal Ganglia in Ovariectomized Rabbits. Biomed Res Int. 2017;2017:2089645 pubmed 出版商
  11. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed 出版商
  12. Helle J, Keiler A, Zierau O, Dörfelt P, Vollmer G, Lehmann L, et al. Effects of the aryl hydrocarbon receptor agonist 3-methylcholanthrene on the 17?-estradiol regulated mRNA transcriptome of the rat uterus. J Steroid Biochem Mol Biol. 2017;171:133-143 pubmed 出版商
  13. Wu D, Kimura F, Zheng L, Ishida M, Niwa Y, Hirata K, et al. Chronic endometritis modifies decidualization in human endometrial stromal cells. Reprod Biol Endocrinol. 2017;15:16 pubmed 出版商
  14. Palma Vera S, Schoen J, Chen S. Periovulatory follicular fluid levels of estradiol trigger inflammatory and DNA damage responses in oviduct epithelial cells. PLoS ONE. 2017;12:e0172192 pubmed 出版商
  15. Ibrahim M, Elwan W. Role of topical dehydroepiandrosterone in ameliorating isotretinoin-induced Meibomian gland dysfunction in adult male albino rat. Ann Anat. 2017;211:78-87 pubmed 出版商
  16. Méndez López L, Zavala Pompa A, Cortés Gutiérrez E, Cerda Flores R, Dávila Rodríguez M. Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors. Arch Med Sci. 2017;13:228-235 pubmed 出版商
  17. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed 出版商
  18. Sánchez Morgan N, Kirsch K, Trackman P, Sonenshein G. UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells. J Cell Biochem. 2017;118:2347-2356 pubmed 出版商
  19. Hopkinson B, Klitgaard M, Petersen O, Villadsen R, Rønnov Jessen L, Kim J. Establishment of a normal-derived estrogen receptor-positive cell line comparable to the prevailing human breast cancer subtype. Oncotarget. 2017;8:10580-10593 pubmed 出版商
  20. Britschgi A, Duss S, Kim S, Couto J, Brinkhaus H, Koren S, et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ER?. Nature. 2017;541:541-545 pubmed 出版商
  21. Gao X, Sun L, Zhang N, Li C, Zhang J, Xiao Z, et al. Gestational Zearalenone Exposure Causes Reproductive and Developmental Toxicity in Pregnant Rats and Female Offspring. Toxins (Basel). 2017;9: pubmed 出版商
  22. Yu H, Jiang Y, Liu L, Shan W, Chu X, Yang Z, et al. Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. Oncotarget. 2017;8:13099-13115 pubmed 出版商
  23. Hill S, Nesser N, Johnson Camacho K, Jeffress M, Johnson A, Boniface C, et al. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst. 2017;4:73-83.e10 pubmed 出版商
  24. Aiello A, Bacci L, Re A, Ripoli C, Pierconti F, Pinto F, et al. MALAT1 and HOTAIR Long Non-Coding RNAs Play Opposite Role in Estrogen-Mediated Transcriptional Regulation in Prostate Cancer Cells. Sci Rep. 2016;6:38414 pubmed 出版商
  25. Brooks S, Dykes A, Schreurs B. A High-Cholesterol Diet Increases 27-Hydroxycholesterol and Modifies Estrogen Receptor Expression and Neurodegeneration in Rabbit Hippocampus. J Alzheimers Dis. 2017;56:185-196 pubmed 出版商
  26. Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, et al. Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. J Pathol. 2017;241:350-361 pubmed 出版商
  27. Pu W, Zhang H, Huang X, Tian X, He L, Wang Y, et al. Mfsd2a+ hepatocytes repopulate the liver during injury and regeneration. Nat Commun. 2016;7:13369 pubmed 出版商
  28. Bonneterre J, Bosq J, Jamme P, Valent A, Gilles E, Zukiwski A, et al. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 2016;1:e000072 pubmed
  29. Cardoso R, Burns A, Moeller J, Skinner D, Padmanabhan V. Developmental Programming: Insulin Sensitizer Prevents the GnRH-Stimulated LH Hypersecretion in a Sheep Model of PCOS. Endocrinology. 2016;157:4641-4653 pubmed
  30. Loverro G, Resta L, Dellino M, Edoardo D, Cascarano M, Loverro M, et al. Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals. Taiwan J Obstet Gynecol. 2016;55:686-691 pubmed 出版商
  31. Harrod A, Fulton J, Nguyen V, Periyasamy M, Ramos Garcia L, Lai C, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 2017;36:2286-2296 pubmed 出版商
  32. Moe Y, Kyi Tha Thu C, Tanaka T, Ito H, Yahashi S, Matsuda K, et al. A Sexually Dimorphic Area of the Dorsal Hypothalamus in Mice and Common Marmosets. Endocrinology. 2016;157:4817-4828 pubmed
  33. Svoronos N, Perales Puchalt A, Allegrezza M, Rutkowski M, Payne K, Tesone A, et al. Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discov. 2017;7:72-85 pubmed 出版商
  34. Nanbo A, Kachi K, Yoshiyama H, Ohba Y. Epstein-Barr virus exploits host endocytic machinery for cell-to-cell viral transmission rather than a virological synapse. J Gen Virol. 2016;97:2989-3006 pubmed 出版商
  35. Sikora M, Jacobsen B, Levine K, Chen J, Davidson N, Lee A, et al. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016;18:92 pubmed 出版商
  36. Nielsen T, Jensen M, Burugu S, Gao D, Jørgensen C, Balslev E, et al. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clin Cancer Res. 2017;23:946-953 pubmed 出版商
  37. Kang M, Jeong K, Kim W, Lee H, Gong G, Suh N, et al. Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. Oncogene. 2017;36:1745-1752 pubmed 出版商
  38. Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T. Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. Oncotarget. 2016;7:74966-74978 pubmed 出版商
  39. Mair B, Konopka T, Kerzendorfer C, Sleiman K, Salic S, Serra V, et al. Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genet. 2016;12:e1006279 pubmed 出版商
  40. Bruner Tran K, Duleba A, Taylor H, Osteen K. Developmental Toxicant Exposure Is Associated with Transgenerational Adenomyosis in a Murine Model. Biol Reprod. 2016;95:73 pubmed 出版商
  41. Chen Q, Zhang H, Liu Y, Adams S, Eilken H, Stehling M, et al. Endothelial cells are progenitors of cardiac pericytes and vascular smooth muscle cells. Nat Commun. 2016;7:12422 pubmed 出版商
  42. Petrovic N, Davidovic R, Jovanovic Cupic S, Krajnovic M, Lukic S, Petrovic M, et al. Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. Mol Diagn Ther. 2016;20:603-615 pubmed
  43. Dhamad A, Zhou Z, Zhou J, Du Y. Systematic Proteomic Identification of the Heat Shock Proteins (Hsp) that Interact with Estrogen Receptor Alpha (ER?) and Biochemical Characterization of the ER?-Hsp70 Interaction. PLoS ONE. 2016;11:e0160312 pubmed 出版商
  44. Ladd B, Mazzola A, Bihani T, Lai Z, BRADFORD J, Collins M, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 2016;7:54120-54136 pubmed 出版商
  45. Shen P, Chen M, He M, Chen L, Song Y, Xiao P, et al. Inhibition of ER?/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. Oncotarget. 2016;7:48501-48516 pubmed 出版商
  46. Lu R, Hu X, Zhou J, Sun J, Zhu A, Xu X, et al. COPS5 amplification and overexpression confers tamoxifen-resistance in ER?-positive breast cancer by degradation of NCoR. Nat Commun. 2016;7:12044 pubmed 出版商
  47. Stock K, Estrada M, Vidic S, Gjerde K, Rudisch A, Santo V, et al. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. Sci Rep. 2016;6:28951 pubmed 出版商
  48. Trapé A, Liu S, Cortés A, Ueno N, Gonzalez Angulo A. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. J Cancer. 2016;7:947-56 pubmed 出版商
  49. Calaf G, Abarca Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett. 2016;11:3637-3642 pubmed
  50. Lu B, Chen Q, Zhang X, Cheng L. Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases. Diagn Pathol. 2016;11:46 pubmed 出版商
  51. Ávila Rodriguez M, Garcia Segura L, Hidalgo Lanussa O, Baez E, Gonzalez J, Barreto G. Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression. Mol Cell Endocrinol. 2016;433:35-46 pubmed 出版商
  52. Simigdala N, Gao Q, Pancholi S, Roberg Larsen H, Zvelebil M, Ribas R, et al. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 2016;18:58 pubmed 出版商
  53. Nguyen A, Yoshida M, Goodarzi H, Tavazoie S. Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness. Nat Commun. 2016;7:11246 pubmed 出版商
  54. Thakkar A, Wang B, Picon Ruiz M, Buchwald P, Ince T. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Res Treat. 2016;157:77-90 pubmed 出版商
  55. Ideta A, Yamashita S, Seki Soma M, Yamaguchi R, Chiba S, Komaki H, et al. Generation of exogenous germ cells in the ovaries of sterile NANOS3-null beef cattle. Sci Rep. 2016;6:24983 pubmed 出版商
  56. Garcia Cuellar M, Büttner C, Bartenhagen C, Dugas M, Slany R. Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes. Cell Rep. 2016;15:310-22 pubmed 出版商
  57. Medina Estrada I, López Meza J, Ochoa Zarzosa A. Anti-Inflammatory and Antimicrobial Effects of Estradiol in Bovine Mammary Epithelial Cells during Staphylococcus aureus Internalization. Mediators Inflamm. 2016;2016:6120509 pubmed 出版商
  58. Irish J, Mills J, Turner Ivey B, Wilson R, Guest S, Rutkovsky A, et al. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ER? in SUM-44 breast cancer cells and is associated with ER? over-expression in breast cancer. Mol Oncol. 2016;10:850-65 pubmed 出版商
  59. Carbognin L, Sperduti I, Brunelli M, Marcolini L, Nortilli R, Pilotto S, et al. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. J Exp Clin Cancer Res. 2016;35:50 pubmed 出版商
  60. Ali H, Stavik B, Myklebust C, Andersen E, Dahm A, Iversen N, et al. Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5'-Flanking Region. PLoS ONE. 2016;11:e0152114 pubmed 出版商
  61. Al Harras M, Houssen M, Shaker M, Farag K, Farouk O, Monir R, et al. Polymorphisms of glutathione S-transferase ? 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility. Oncol Lett. 2016;11:2182-2188 pubmed
  62. Tran Q, Firkins R, Giles J, Francis S, Matnishian V, Tran P, et al. Estrogen Enhances Linkage in the Vascular Endothelial Calmodulin Network via a Feedforward Mechanism at the G Protein-coupled Estrogen Receptor 1. J Biol Chem. 2016;291:10805-23 pubmed 出版商
  63. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed 出版商
  64. Zhao Y, Xu L, Qiao Z, Gao L, Ding S, Ying X, et al. YiXin-Shu, a ShengMai-San-based traditional Chinese medicine formula, attenuates myocardial ischemia/reperfusion injury by suppressing mitochondrial mediated apoptosis and upregulating liver-X-receptor α. Sci Rep. 2016;6:23025 pubmed 出版商
  65. Matsumoto H, Thike A, Li H, Yeong J, Koo S, Dent R, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156:237-47 pubmed 出版商
  66. Alkner S, Bendahl P, Ehinger A, Lövgren K, Rydén L, Fernö M. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE. 2016;11:e0150977 pubmed 出版商
  67. Kobayashi Y, Yamamoto Y, Kageyama S, Hirayama H, Kimura K, Okuda K. Regulation of bovine oviductal NO synthesis by follicular steroids and prostaglandins. Reproduction. 2016;151:577-87 pubmed 出版商
  68. Villa Diaz L, Kim J, Laperle A, Palecek S, Krebsbach P. Inhibition of Focal Adhesion Kinase Signaling by Integrin ?6?1 Supports Human Pluripotent Stem Cell Self-Renewal. Stem Cells. 2016;34:1753-64 pubmed 出版商
  69. Cammas A, Lacroix Triki M, Pierredon S, Le Bras M, Iacovoni J, Teulade Fichou M, et al. hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget. 2016;7:16793-805 pubmed 出版商
  70. Kim S, Kim E, Lee H, Kim M, Yoon J, Koo J, et al. Asymptomatic Benign Papilloma Without Atypia Diagnosed at Ultrasonography-Guided 14-Gauge Core Needle Biopsy: Which Subgroup can be Managed by Observation?. Ann Surg Oncol. 2016;23:1860-6 pubmed 出版商
  71. Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed 出版商
  72. Nair H, Baker R, Owston M, Escalona R, Dick E, Vandeberg J, et al. An efficient model of human endometriosis by induced unopposed estrogenicity in baboons. Oncotarget. 2016;7:10857-69 pubmed 出版商
  73. Ma Y, Guo H, Zhang L, Tao L, Yin A, Liu Z, et al. Estrogen replacement therapy-induced neuroprotection against brain ischemia-reperfusion injury involves the activation of astrocytes via estrogen receptor β. Sci Rep. 2016;6:21467 pubmed 出版商
  74. Kavlashvili T, Jia Y, Dai D, Meng X, Thiel K, Leslie K, et al. Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer. PLoS ONE. 2016;11:e0148912 pubmed 出版商
  75. Ho J, Chang F, Huang F, Liu J, Liu Y, Chen S, et al. Estrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway. PLoS ONE. 2016;11:e0148301 pubmed 出版商
  76. Varešlija D, McBryan J, Fagan A, Redmond A, Hao Y, Sims A, et al. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. Clin Cancer Res. 2016;22:2765-77 pubmed 出版商
  77. Vacca V, Marinelli S, Pieroni L, Urbani A, Luvisetto S, Pavone F. 17beta-estradiol counteracts neuropathic pain: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice. Sci Rep. 2016;6:18980 pubmed 出版商
  78. Piggin C, Roden D, Gallego Ortega D, Lee H, Oakes S, Ormandy C. ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Res. 2016;18:4 pubmed 出版商
  79. El Gendi S, Mostafa M. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma. Pathol Oncol Res. 2016;22:461-70 pubmed 出版商
  80. Fridriksdottir A, Kim J, Villadsen R, Klitgaard M, Hopkinson B, Petersen O, et al. Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture. Nat Commun. 2015;6:8786 pubmed 出版商
  81. Alayev A, Salamon R, Berger S, Schwartz N, Cuesta R, Snyder R, et al. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation. Oncogene. 2016;35:3535-43 pubmed 出版商
  82. González Morán M. Immunohistochemical localization of progesterone receptor isoforms and estrogen receptor alpha in the chicken oviduct magnum during development. Acta Histochem. 2015;117:681-7 pubmed 出版商
  83. Wunsch E, Klak M, Wasik U, Milkiewicz M, Blatkiewicz M, Urasinska E, et al. Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR. J Immunol Res. 2015;2015:571353 pubmed 出版商
  84. O Shaughnessy J, Campone M, Brain E, Neven P, Hayes D, Bondarenko I, et al. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol. 2016;27:106-13 pubmed 出版商
  85. Soares M, Correia J, Peleteiro M, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053-64 pubmed 出版商
  86. Kokkinopoulos I, Ishida H, Saba R, Ruchaya P, Cabrera C, Struebig M, et al. Single-Cell Expression Profiling Reveals a Dynamic State of Cardiac Precursor Cells in the Early Mouse Embryo. PLoS ONE. 2015;10:e0140831 pubmed 出版商
  87. Xiong W, Zhang L, Yu L, Xie W, Man Y, Xiong Y, et al. Estradiol promotes cells invasion by activating β-catenin signaling pathway in endometriosis. Reproduction. 2015;150:507-16 pubmed 出版商
  88. Radhika N, Govindaraj V, Sarangi S, Rao A. Neonatal exposure to 17β-estradiol down-regulates the expression of synaptogenesis related genes in selected brain regions of adult female rats. Life Sci. 2015;141:1-7 pubmed 出版商
  89. Xue X, Yang Y, Zhang A, Fong K, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35:2746-55 pubmed 出版商
  90. Jung Y, Kim H, Koo J. Expression of Lipid Metabolism-Related Proteins in Metastatic Breast Cancer. PLoS ONE. 2015;10:e0137204 pubmed 出版商
  91. Coelho R, Calaça I, Celestrini D, Correia Carneiro A, Costa M, Zancan P, et al. Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma. Oncotarget. 2015;6:29375-87 pubmed 出版商
  92. Gómez R, Ossa C, Montoya M, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562 pubmed 出版商
  93. Slaats G, Saldivar J, Bacal J, Zeman M, Kile A, Hynes A, et al. DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome. J Clin Invest. 2015;125:3657-66 pubmed 出版商
  94. Hsu P, Hsu H, Hsiao T, Ye Z, Wang E, Profit A, et al. Spatiotemporal control of estrogen-responsive transcription in ERα-positive breast cancer cells. Oncogene. 2016;35:2379-89 pubmed 出版商
  95. Malaterre J, Pereira L, Putoczki T, Millen R, Paquet Fifield S, Germann M, et al. Intestinal-specific activatable Myb initiates colon tumorigenesis in mice. Oncogene. 2016;35:2475-84 pubmed 出版商
  96. KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed 出版商
  97. Adachi K, Miki Y, Saito R, Hata S, Yamauchi M, Mikami Y, et al. Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis. Hum Pathol. 2015;46:1685-93 pubmed 出版商
  98. Zhang Y, Wei X, Liang Y, Chen W, Zhang F, Bai J, et al. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation. PLoS ONE. 2015;10:e0135851 pubmed 出版商
  99. Montt Guevara M, Giretti M, Russo E, Giannini A, Mannella P, Genazzani A, et al. Estetrol Modulates Endothelial Nitric Oxide Synthesis in Human Endothelial Cells. Front Endocrinol (Lausanne). 2015;6:111 pubmed 出版商
  100. McBryan J, Fagan A, McCartan D, Bane F, VareÅ¡lija D, Cocchiglia S, et al. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clin Cancer Res. 2015;21:5371-9 pubmed 出版商
  101. Bacallao K, Plaza Parrochia F, Cerda A, Gabler F, Romero C, Vantman D, et al. Levels of Regulatory Proteins Associated With Cell Proliferation in Endometria From Untreated Patients Having Polycystic Ovarian Syndrome With and Without Endometrial Hyperplasia. Reprod Sci. 2016;23:211-8 pubmed 出版商
  102. Rowson Hodel A, Manjarin R, Trott J, Cardiff R, Borowsky A, Hovey R. Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo. BMC Cancer. 2015;15:562 pubmed 出版商
  103. Shah S, Miller P, Garcia Contreras M, Ao Z, Machlin L, Issa E, et al. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype. Cancer Biol Ther. 2015;16:1671-81 pubmed 出版商
  104. Wardell S, Nelson E, Chao C, Alley H, McDonnell D. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocr Relat Cancer. 2015;22:713-24 pubmed 出版商
  105. Felzen V, Hiebel C, Koziollek Drechsler I, Reißig S, Wolfrum U, Kögel D, et al. Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function. Cell Death Dis. 2015;6:e1812 pubmed 出版商
  106. Kawai M, Nakashima A, Kamada S, Kikkawa U. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family. J Biomed Sci. 2015;22:48 pubmed 出版商
  107. Mundim F, Pasini F, Brentani M, Soares F, Nonogaki S, Waitzberg A. MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases. Mol Clin Oncol. 2015;3:506-514 pubmed
  108. Cheung S, Boey Y, Koh V, Thike A, Lim J, Iqbal J, et al. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:489-98 pubmed 出版商
  109. Ma S, Yin N, Qi X, Pfister S, Zhang M, Ma R, et al. Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). Oncotarget. 2015;6:13320-33 pubmed
  110. Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152:293-304 pubmed 出版商
  111. Winczura P, SosiÅ„ska Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, et al. Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients. Pathol Oncol Res. 2015;21:1229-36 pubmed 出版商
  112. Ferguson D, Long D, Smith M, Craig Owens L, Means J, Fadare O, et al. Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas. J Ovarian Res. 2015;8:34 pubmed 出版商
  113. de Deus Moura R, Carvalho F, Bacchi C. Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old. Breast. 2015;24:461-7 pubmed 出版商
  114. Teng Y, Radde B, Litchfield L, Ivanova M, Prough R, Clark B, et al. Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015;290:15799-811 pubmed 出版商
  115. Nwafor C, Keshinro S. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger J Clin Pract. 2015;18:553-8 pubmed 出版商
  116. Frithiof H, Welinder C, Larsson A, Rydén L, Aaltonen K. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med. 2015;13:126 pubmed 出版商
  117. Zhao H, Agazie Y. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. BMC Cancer. 2015;15:109 pubmed 出版商
  118. de los Ángeles Carrasco Ruiz M, García Villamar V, López García K, Sánchez García O, Pacheco P, Cuevas E, et al. Aromatase expression is linked to estrogenic sensitivity of periurethral muscles in female rabbits. Cell Biochem Funct. 2015;33:188-95 pubmed 出版商
  119. Lee J, Garbe J, Vrba L, Miyano M, Futscher B, Stampfer M, et al. Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells. Front Cell Dev Biol. 2015;3:13 pubmed 出版商
  120. Tkalia I, Vorobyova L, Grabovoy A, Svintsitsky V, Tarasova T. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats. Exp Oncol. 2015;37:30-5 pubmed
  121. Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, et al. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget. 2015;6:8103-14 pubmed
  122. Carnesecchi J, Malbouyres M, de Mets R, Balland M, Beauchef G, Vié K, et al. Estrogens induce rapid cytoskeleton re-organization in human dermal fibroblasts via the non-classical receptor GPR30. PLoS ONE. 2015;10:e0120672 pubmed 出版商
  123. Geels Y, van der Putten L, van Tilborg A, Lurkin I, Zwarthoff E, Pijnenborg J, et al. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol. 2015;137:245-51 pubmed 出版商
  124. Eom K, Jang M, Park S, Kang E, Kim S, Kim J, et al. The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer. Cancer Res Treat. 2016;48:125-32 pubmed 出版商
  125. Rusz O, Vörös A, Varga Z, Kelemen G, Uhercsák G, Nikolényi A, et al. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer. Pathol Oncol Res. 2015;21:977-84 pubmed 出版商
  126. Kim S, Lee Y, Koo J. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS ONE. 2015;10:e0119473 pubmed 出版商
  127. Hussain I, Bhan A, Ansari K, Deb P, Bobzean S, Perrotti L, et al. Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer. Biochim Biophys Acta. 2015;1849:697-708 pubmed 出版商
  128. Heskamp S, Boerman O, Molkenboer Kuenen J, Wauters C, Strobbe L, Mandigers C, et al. Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. PLoS ONE. 2015;10:e0117745 pubmed 出版商
  129. Oon M, Thike A, Tan S, Tan P. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast Cancer Res Treat. 2015;150:31-41 pubmed 出版商
  130. Simons M, Nagtegaal I, Overbeek L, Flucke U, Massuger L, Bulten J. A patient with a noninvasive mucinous ovarian borderline tumor presenting with late pleural metastases. Int J Gynecol Pathol. 2015;34:143-50 pubmed 出版商
  131. Argon A, Åžener A, ZekioÄŸlu O, Kapkaç M, Özdemir N. The effect of freezing on the immunoprofile of breast carcinoma cells. Balkan Med J. 2014;31:335-9 pubmed 出版商
  132. Park S, Kim H, Koo J. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat. 2015;149:727-41 pubmed 出版商
  133. Hole S, Pedersen A, Hansen S, Lundqvist J, Yde C, Lykkesfeldt A. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. 2015;46:1481-90 pubmed 出版商
  134. Ammar A, Esmat A, Hassona M, Tadros M, Abdel Naim A, Guns E. The effect of pomegranate fruit extract on testosterone-induced BPH in rats. Prostate. 2015;75:679-92 pubmed 出版商
  135. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz E, Cappello A, et al. Effects of atrazine on estrogen receptor α- and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblasts. Environ Health Perspect. 2015;123:493-9 pubmed 出版商
  136. Liu Q, Hu T, He L, Huang X, Tian X, Zhang H, et al. Genetic targeting of sprouting angiogenesis using Apln-CreER. Nat Commun. 2015;6:6020 pubmed 出版商
  137. Papanikolaou V, Stefanou N, Dubos S, Papathanasiou I, Palianopoulou M, Valiakou V, et al. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes. Cell Oncol (Dordr). 2015;38:155-64 pubmed 出版商
  138. Doberstein K, Milde Langosch K, Bretz N, Schirmer U, Harari A, Witzel I, et al. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. BMC Cancer. 2014;14:958 pubmed 出版商
  139. Yang Z, Broz D, Noderer W, Ferreira J, Overton K, Spencer S, et al. p53 suppresses muscle differentiation at the myogenin step in response to genotoxic stress. Cell Death Differ. 2015;22:560-73 pubmed 出版商
  140. Liu J, Yu Y, Sun J, He S, Wang X, Yin J, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015;149:133-40 pubmed 出版商
  141. Van Bragt M, Hu X, Xie Y, Li Z. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. elife. 2014;3:e03881 pubmed 出版商
  142. Ohoka N, Nagai K, Hattori T, Okuhira K, Shibata N, Cho N, et al. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis. 2014;5:e1513 pubmed 出版商
  143. Schillace R, Skinner A, Pommier R, O Neill S, Muller P, Naik A, et al. Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations. BMC Cancer. 2014;14:733 pubmed 出版商
  144. Tkalia I, Vorobyova L, Grabovoy A, Svintsitsky V, Tarasova T, Lukyanova N, et al. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor. Exp Oncol. 2014;36:184-90 pubmed
  145. Baccelli I, Stenzinger A, Vogel V, Pfitzner B, Klein C, Wallwiener M, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget. 2014;5:8147-60 pubmed
  146. Crider A, Thakkar R, Ahmed A, Pillai A. Dysregulation of estrogen receptor beta (ERβ), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects. Mol Autism. 2014;5:46 pubmed 出版商
  147. Carvalho F, Bacchi L, Pincerato K, van de Rijn M, Bacchi C. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102 pubmed 出版商
  148. Oguz Erdogan A, Ozdemirler N, Oyken M, Alper M, Erson Bensan A. ARID3B expression in primary breast cancers and breast cancer-derived cell lines. Cell Oncol (Dordr). 2014;37:289-96 pubmed 出版商
  149. Li L, Wang Q, Lv X, Sha L, Qin H, Wang L, et al. Expression and localization of estrogen receptor in human breast cancer and its clinical significance. Cell Biochem Biophys. 2015;71:63-8 pubmed 出版商
  150. Peña C, Champagne F. Neonatal overexpression of estrogen receptor-? alters midbrain dopamine neuron development and reverses the effects of low maternal care in female offspring. Dev Neurobiol. 2015;75:1114-24 pubmed 出版商
  151. Mingels M, Masadah R, Geels Y, Otte Holler I, de Kievit I, van der Laak J, et al. High prevalence of atypical hyperplasia in the endometrium of patients with epithelial ovarian cancer. Am J Clin Pathol. 2014;142:213-21 pubmed 出版商
  152. Syed B, Green A, Nolan C, Morgan D, Ellis I, Cheung K. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. PLoS ONE. 2014;9:e100573 pubmed 出版商
  153. Ucher A, Ranjit S, Kadungure T, Linehan E, Khair L, Xie E, et al. Mismatch repair proteins and AID activity are required for the dominant negative function of C-terminally deleted AID in class switching. J Immunol. 2014;193:1440-50 pubmed 出版商
  154. Wright P, Jones S, Ardern N, Ward R, Clarke R, Sotgia F, et al. 17?-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells. Oncotarget. 2014;5:3055-65 pubmed
  155. Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014;16:R53 pubmed 出版商
  156. Tannour Louet M, Han S, Louet J, Zhang B, Romero K, Addai J, et al. Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action. Nat Med. 2014;20:715-24 pubmed 出版商
  157. Ordonez N, Sahin A. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Hum Pathol. 2014;45:1529-40 pubmed 出版商
  158. Varghese F, Bukhari A, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9:e96801 pubmed 出版商
  159. Sui S, He B, Jia Y, Li R, Cai D, Li X, et al. Maternal protein restriction during gestation and lactation programs offspring ovarian steroidogenesis and folliculogenesis in the prepubertal gilts. J Steroid Biochem Mol Biol. 2014;143:267-76 pubmed 出版商
  160. Alexandre Pires G, Martins C, Galvão A, Correia M, Ramilo D, Quaresma M, et al. Morphological aspects and expression of estrogen and progesterone receptors in the interdigital sinus in cyclic ewes. Microsc Res Tech. 2014;77:313-25 pubmed
  161. van der Post R, Bult P, Vogelaar I, Ligtenberg M, Hoogerbrugge N, van Krieken J. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch. 2014;464:673-9 pubmed 出版商
  162. Wong P, Yeoh C, Ahmad A, Chelala C, Gillett C, Speirs V, et al. Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer. Oncogene. 2014;33:4579-88 pubmed 出版商
  163. Bouchekioua Bouzaghou K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, et al. LKB1 when associated with methylatedER? is a marker of bad prognosis in breast cancer. Int J Cancer. 2014;135:1307-18 pubmed 出版商
  164. Liu Y, Nenutil R, Appleyard M, Murray K, Boylan M, Thompson A, et al. Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer. 2014;110:2063-71 pubmed 出版商
  165. Gao L, Yue M, Davis J, Hyjek E, Schuger L. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch. 2014;464:495-503 pubmed 出版商
  166. Neumeister V, Parisi F, England A, Siddiqui S, Anagnostou V, Zarrella E, et al. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Lab Invest. 2014;94:467-74 pubmed 出版商
  167. Kővári B, Rusz O, Schally A, Kahan Z, Cserni G. Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive. APMIS. 2014;122:824-31 pubmed 出版商
  168. Booth M, Hanby A, Speirs V. Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Res Treat. 2014;143:605-7 pubmed 出版商
  169. Jordan N, Dutkowski C, Barrow D, Mottram H, Hutcheson I, Nicholson R, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res. 2014;16:R12 pubmed 出版商
  170. Park H, Jang M, Kim E, Kim H, Lee H, Kim Y, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27:1212-22 pubmed 出版商
  171. Chavez Valdez R, Martin L, Razdan S, Gauda E, Northington F. Sexual dimorphism in BDNF signaling after neonatal hypoxia-ischemia and treatment with necrostatin-1. Neuroscience. 2014;260:106-19 pubmed 出版商
  172. Samaan S, Tranchevent L, Dardenne E, Polay Espinoza M, Zonta E, Germann S, et al. The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways. Nucleic Acids Res. 2014;42:2197-207 pubmed 出版商
  173. Faupel Badger J, Duggan M, Sherman M, Garcia Closas M, Yang X, Lissowska J, et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5:42-50 pubmed 出版商
  174. Yoshimaru T, Komatsu M, Matsuo T, Chen Y, Murakami Y, Mizuguchi K, et al. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun. 2013;4:2443 pubmed 出版商
  175. Kusafuka K, Onitsuka T, Muramatsu K, Miki T, Murai C, Suda T, et al. Salivary duct carcinoma with rhabdoid features: report of 2 cases with immunohistochemical and ultrastructural analyses. Head Neck. 2014;36:E28-35 pubmed 出版商
  176. Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E, et al. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer. 2014;134:1112-22 pubmed 出版商
  177. Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013;6:1380-91 pubmed
  178. Kourelis K, Tsue T, Girod D, Tawfik O, Sykes K, Shnayder Y. Negative prognostic factors for head and neck cancer in the young. J BUON. 2013;18:459-64 pubmed
  179. Aguiar F, Mendes H, Cirqueira C, Bacchi C, Carvalho F. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. Clinics (Sao Paulo). 2013;68:638-43 pubmed 出版商
  180. Hao J, Yang C, Liu F, Yang Y, Li S, Li W, et al. Accessory breast cancer occurring concurrently with bilateral primary invasive breast carcinomas: a report of two cases and literature review. Cancer Biol Med. 2012;9:197-201 pubmed 出版商
  181. Im S, Choi H, Yoo C, Jung J, Jeon Y, Suh Y, et al. Hedgehog related protein expression in breast cancer: gli-2 is associated with poor overall survival. Korean J Pathol. 2013;47:116-23 pubmed 出版商
  182. Palmieri C, Gojis O, Rudraraju B, Stamp Vincent C, Wilson D, Langdon S, et al. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer. 2013;108:2039-44 pubmed 出版商
  183. Zhao Y, Li W, Lang R, Yang Y, Gao X, Zheng Y, et al. Primary acinic cell carcinoma of the breast: a case report and review of the literature. Int J Surg Pathol. 2014;22:177-81 pubmed 出版商
  184. Yang B, Ma C, Chen Z, Yi W, McNutt M, Wang Y, et al. Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer. PLoS ONE. 2013;8:e58706 pubmed 出版商
  185. Ward J, Rider V, Abdou N, Kimler B. Estradiol differentially regulates calreticulin: a potential link with abnormal T cell function in systemic lupus erythematosus?. Lupus. 2013;22:583-96 pubmed 出版商
  186. Corrêa N, Kuasne H, Faria J, Seixas C, Santos I, Abreu F, et al. Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors. Oncol Rep. 2013;29:1299-307 pubmed 出版商
  187. Welsh A, Harigopal M, Wimberly H, Prasad M, Rimm D. Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol. 2013;21:139-47 pubmed 出版商
  188. Carvalho F, Carvalho J, Pereira R, Ceccato B, Lacordia R, Baracat E. Leiomyomatosis peritonealis disseminata associated with endometriosis and multiple uterus-like mass: report of two cases. Clin Med Insights Case Rep. 2012;5:63-8 pubmed 出版商
  189. Cheah P, Looi L, Lee G, Teoh K, Mun K, Nazarina A. Unusual finding of endocervical-like mucinous epithelium in continuity with urothelium in endocervicosis of the urinary bladder. Diagn Pathol. 2011;6:56 pubmed 出版商
  190. Teng Y, Tan W, Thike A, Cheok P, Tse G, Wong N, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35 pubmed 出版商
  191. Rasmussen L, Frederiksen K, Din N, Galsgaard E, Christensen L, Berchtold M, et al. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr Relat Cancer. 2010;17:809-22 pubmed 出版商
  192. Leong A, Haffajee Z. Citraconic anhydride: a new antigen retrieval solution. Pathology. 2010;42:77-81 pubmed 出版商
  193. Kim T, Huh J, Lee S, Kang H, Kim G, An H. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology. 2008;53:48-55 pubmed 出版商
  194. Shi S, Liu C, Pootrakul L, Tang L, Young A, Chen R, et al. Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. Am J Clin Pathol. 2008;129:358-66 pubmed 出版商
  195. Dhasarathy A, Kajita M, Wade P. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol. 2007;21:2907-18 pubmed
  196. Duss S, André S, Nicoulaz A, Fiche M, Bonnefoi H, Brisken C, et al. An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res. 2007;9:R38 pubmed
  197. Rao K, Alper O, Opheim K, Bonnet G, Wolfe K, Bryant E, et al. Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells. Cancer Cell Int. 2006;6:15 pubmed
  198. Jones L, Li M, Halama E, Ma Y, Lubet R, Grubbs C, et al. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene. 2005;24:3554-62 pubmed
  199. Kuo K, Chen M, Lin M. Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature. Am J Surg Pathol. 2004;28:405-9 pubmed
  200. Goyal H, Braden T, Williams C, Dalvi P, Mansour M, Mansour M, et al. Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: a developmental and immunocytochemical study. Biol Reprod. 2004;70:1504-17 pubmed
  201. Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D. Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination. Int J Gynecol Cancer. 2003;13:32-7 pubmed
  202. Herbert M, Sandbank J, Liokumovich P, Yanai O, Pappo I, Karni T, et al. Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases. Histopathology. 2002;41:30-4 pubmed
  203. Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol. 2001;20:341-5 pubmed
  204. Park W, Choi J, Hwang E, Lee J. Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas. Clin Cancer Res. 1996;2:2029-35 pubmed